PNPLA3 and metabolic dysfunction-associated steatohepatitis: Moreover, a direct stimulation of PPARγ signalling in HSCs from PNPLA3 I148M patients, where PPARγ signalling is attenuated,22 would translate into a synergic therapeutic effect perhaps explaining the beneficial effects obtained on fibrosis in NASH cohorts treated with PPARγ agonist.50